Basurto L, Zárate A, Córdova N, Saucedo R, Galván R, Campos S, Hernández M

Language: Spanish
References: 12
Page: 227-230
PDF size: 335.66 Kb.

ABSTRACT

Introduction: Osteoporosis is the most common skeletal disorder and is considered a risk of fracture. Most medication used for the treatment of osteoporosis are antiresorptive; however strontium therapy in postmenopausal women has shown a double effect on resorption and bone formation.
Objective: To evaluate the effect of strontium on bone mineral density (BMD) and circulating biochemical markers of bone turnover in postmenopausal women who had a decreased BMD.
Material and methods: A prospective study was carried out in 23 postmenopausal women who had decreased BMD, who received daily strontium orally by night during 12 months. Evaluation of BMD at lumbar spine and hip as well as biochemical markers in blood for bone turnover before and during therapy.
Results: BMD at the spine (0.755 ± 0.104 to 0.792 ± 0.094, p ‹ 0.05) and hip (0.833 ± 0.096 to 0.856 ± 0.100, p ‹ 0.05) increased significantly after 12 months of treatment. Bone turnover markers showed a decrement of osteocalcin, by contrast the specific alkaline phosphatase increased after 6 months of therapy; however C-terminal telopeptide of type 1 collagen was not modified.
Conclusions: Strontium ranelate increased significantly BMD at the spine and at the hip in postmenopausal women and simultaneously improved bone turnover estimated by circulating bone markers.

REFERENCES

1. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359:1841-50.

2. Qaseem A, Shekelle P, Hopkins R, Forciea MA, Owens DK. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Int Med 2008;149:404-15.

3. Lane NE, Kelman A. A review of anabolic therapies for osteoporosis. Arthritis Res Ther 2003;5:214-12.

4. Reginster JY. Strontium ranelate in osteoporosis. Curr Pharm Des 2002; 8:1907-16.

5. Choudhary S, Halbout P, Alander C, Raisz L, Pilbeam C. Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: involvement of prostaglandins. J Bone Miner Res 2007;22:1002-10.

6. Atkins GJ, Welldon KJ, Halbout P, Findlay DM. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 2009;20:653-64.

7. Meunier PJ, Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.

8. Reginster JY, Meunier PJ. Strontium ranelate phase 2 doseranging studies: PREVOS and STRATOS studies. Osteoporosis Int 2003; 14:S56-65.

9. Reginster JY, Seeman E, De Vernejoul MC, Adami S, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22.

10. Reginster JY, Deroisy R, Dougados M, Jupsin I, et al. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, doseranging, placebo-controlled PREVOS trial. Osteoporos Int 2002;13:925-31.

11. Blake GM, Fogelman I. The correction of BMD measurements for bone strontium content. J Clin Densitom 2007;10:259-65.

12. Ammann P, Badoud I, Barraud S, Dayer R, Rizzoli R. Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 2007;22:1419-25.